معرفی
Anna Blom is a Professor and Principal Investigator at Lund University, leading research in the Department of Translational Medicine and contributing to major initiatives like EXODIAB: Excellence of Diabetes Research in Sweden and LUCC: Lund University Cancer Centre. Her work bridges immunology, cancer research, and microbiology, focusing on the complement system's dual roles in health and disease.
- Assistant Head of Department, Department of Translational Medicine
- Research Team Manager, Protein Chemistry, Malmö
- Principal Investigator, LUCC and EXODIAB
Research Interests: Blom's group investigates complement system regulation, particularly its pro-inflammatory contributions to cancer development (breast, prostate, leukemias, lymphomas) and rheumatic diseases (rheumatoid arthritis, lupus). They explore novel regulators like CSMD1 and COMP, aiming to improve diagnostics and treatments. Recent projects address intracellular complement (CD59 in diabetes, C3 in autophagy) and bacterial immune evasion strategies.
Scientific Contributions: Her research has been recognized with prestigious awards such as the Berzeliusmedaljen (2021) and Doctor Honoris Causa at Rzeszow University (2018). She has received grants from the Knut and Alice Wallenberg Foundation, Swedish Research Council, and Alzheimerfonden.
- Keynote Speaker: 7th Swedish Cancer Research Meeting (2025)
- Advising: Supervised PhD students on complement's role in cancer and bacterial pathogenesis
- Labs/Teams: Protein Chemistry, Malmö; LUCC; EXODIAB
